

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

**THIS PAGE BLANK (USPTO)**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification n<sup>o</sup> 4 :C07K 5/06, A61K 37/02  
// C07K 5/02

A1

(11) International Publication Number:

WO 86/02353

(43) International Publication Date:

24 April 1986 (24.04.86)

(21) International Application Number: PCT/EP85/00543

(22) International Filing Date: 16 October 1985 (16.10.85)

(31) Priority Application Number: 23173 A/84

(32) Priority Date: 16 October 1984 (16.10.84)

(33) Priority Country: IT

(71) Applicant (for all designated States except US): ZAMBON S.p.A. [IT/IT]; Via della Chimica, 9, I-36100 Vicenza (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PILOTTO, Alberto [IT/IT]; Via Durando 35, I-36100 Vicenza (IT). PORTELLI, Mario [IT/IT]; Viale Milano 37, I-36100 Vicenza (IT). CARENZI, Angelo [IT/IT]; Via Rossini 9, I-21052 Busto Arsizio (Varese) (IT). DELLA BELLA, Davide [IT/IT]; Piazza Leonardo da Vinci 3, I-20133 Milano (IT).

(74) Agent: WEINHOLD, Peter; Patentanwälte Schmied-Kowarzik, Weinhold, Barz, Dannenberg, Gudel, Schubert, Siegfriedstrasse 8, D-8000 München 40 (DE).



(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.

## Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: DIPEPTIDE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY AND COMPOSITIONS CONTAINING THEM



## (57) Abstract

The compounds of formula (I) wherein the group (II) represents the residue of a natural amino acid selected from the group consisting of glycine, alanine, beta-alanine, phenylalanine, isoleucine, methionine, proline, aspartic acid and arginine; R represents a hydrogen atom or a C<sub>1</sub>-C<sub>4</sub> alkyl; and their acid-addition salts with pharmaceutically acceptable organic or inorganic acids; are useful in the preventive and curative treatment of pathologic syndromes due to the lowering of glutathione (GSH) levels.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				


# DIPEPTIDE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY AND COMPOSITIONS CONTAINING THEM

- 1 -

The present invention concerns compounds having pharmaceutical activity and more particularly it concerns dipeptide compounds and their use in the preventive and curative treatment of pathologic syndromes deriving from low intracellular glutathione (GSn) levels.

The invention concerns also pharmaceutical preparations containing said dipeptides as active ingredient.

An object of the invention are the compounds of formula




wherein the group  $\text{-N}-(\text{Y})-\text{COOR}$   
 $\quad \quad \quad |$   
 $\quad \quad \quad \text{X}$


- 15 represents the residue of a natural amino acid selected from the group consisting of glycine, alanine, beta-alanine, phenylalanine, isoleucine, methionine, proline, aspartic acid and arginine, R represents a hydrogen atom or a  $\text{C}_1\text{-C}_4$  alkyl, and their acid-addition salts with pharmaceutically acceptable organic or inorganic acids.

Specific examples of the compounds of formula I are:

- (2-methyl-thiazolidin-4-carbonyl)-glycine and the esters thereof, of formula




- (2-methyl-thiazolidin-4-carbonyl)-alanine and the esters thereof, of formula




- 2 -


- (2-methyl-thiazolidin-4-carbonyl)-beta-alanine and the esters thereof, of formula




- (2-methyl-thiazolidin-4-carbonyl)-phenylalanine and the esters thereof, of formula




- (2-methyl-thiazolidin-4-carbonyl)-isoleucine and the esters thereof, of formula



- (2-methyl-thiazolidin-4-carbonyl)-methionine and the esters thereof, of formula




- (2-methyl-thiazolidin-4-carbonyl)-proline and the esters thereof, of formula




- 3 -

- (2-methyl-thiazolidin-4-carbonyl)-aspartic acid and the esters thereof, of formula




- (2-methyl-thiazolidin-4-carbonyl)-arginine and the esters thereof, of formula



and the pharmaceutically acceptable salts thereof.

- 15 In the above compounds (I-a,i),  $\text{R}_1$  is the group



and R is a hydrogen atom or a  $\text{C}_1 - \text{C}_4$  alkyl.

- 20 The preparation of the compounds of formula I is carried out by condensing 2-methyl-thiazolidine-4-carboxylic acid, suitably protected on the nitrogen atom, with an ester of the selected amino acid in the presence of a coupling agent.

A suitable protecting group is, for example, the t-butoxycarbonyl group.

As coupling agent, dicyclohexylcarbodiimide in the presence of N-hydroxy-benzotriazole may be used.

By removal of the protecting group, the esters of formula I are obtained; from these, if desired, the free acids are obtained by hydrolysis.

- 4 -

Alternatively the hydrolysis may precede the removal of the protecting group on the nitrogen atom of the 2-methyl-thiazolidine-4-carboxylic moiety.

- 5 When the amino acid to be condensed with 2-methyl-thiazolidine-4-carboxylic acid is aspartic acid or arginine it is advisable that the second carboxy group or respectively amino group of said amino acids, be protected.

The protection and the liberation of said groups is carried out  
10 according to methods known in the chemistry of amino acids.

The preparation of the acid addition salts is carried out according to usual procedures.

It is evident for the expert in the field that the compounds of formula I have asymmetric carbon atoms and thus they exist in the  
15 form of various stereoisomers.

If desired, it is possible to separate the stereoisomers according to usual procedures both as final products and as intermediates.

The single isomers as well as their mixtures are comprised in the scope of the present invention.

- 20 The compounds of the invention have shown to be able to promote the reconstitution of the cellular content in glutathione (GSH) and to provide an effective protection against the cellular damages caused by endogenous as well as exogenous toxic factors.

GSH is, at intracellular level, the antidote physiologically  
25 appointed to the neutralization and thus detoxication, by the formation of covalent bonds, from highly reactive toxic substances of endogenous or exogenous origin.

Depletion in GSH involves the starting of cellular degeneration and necrosis processes (Larsson et al. eds., "Function of GSH",  
30 Raven Press, N.Y., 1983).



- 5 -

The compounds of the invention have shown to be endowed also with positive characteristics of bioavailability and general and local tolerability.

5 Thus, they are useful drugs suitable in the prevention and in the treatment of pathologic syndromes in which the aetiopathogenic origin is the depletion in GSH content in the parenchymal organs or in the mesenchymal cellular population, said depletion being due to interaction with metabolic intermediates having endogenous  
10 origin, for example toxigenic, as well as exogenous, for example exposure to noxious chemicals.

These syndromes may affect various organs and tissues and may be expressed as toxic or toxigenic hepatopathy, as sub-acute or chronic respiratory affection of infective origin (for example  
15 bronchitis) or due to inhalation of extraneous substances (for example in smokers), as arthritis, as central or peripheral neuropathy with degenerative components, as degenerative cardiopathy during chemotherapy.

The activity of the compounds of the invention on the intracellular GSH levels was tested on animals (mouse) in which a depletion  
20 of GSH was previously induced by treatment with p-acetamino-phenol (NAPA) in standard conditions.

The GSH levels in the animals liver were determined before the treatment with NAPA and 30 and 60 minutes thereafter (Mitchell  
25 J.R. et al., J. Pharmacol. Exptl. Ther., 187, 185-194, 1973), according to a modification of the procedure described by Hissin et al. (Anal. Biochem., 74, 214-226, 1976).

All the tested compounds showed to be highly effective under the used experimental conditions and in both oral and parenteral  
30 administration; already after 30 minutes a meaningful increase in

- 6 -

the intracellular GSH level was observed with respect to untreated controls.

After 60 minutes, the GSH level was further increased reaching about 70% of that of witness mice.

5 The standard experimental test selected to demonstrate the protective characteristics of the compounds of invention against toxic substances in the sound animal was the test in which a lethal dose of NAPA is administered to the mouse (Alnava E. et al., Acta  
10 Pharmacol. et Toxicol., 42, 317-319, 1978).

The reduction of mortality was evaluated when the compound under examination was administered contemporaneously with the toxic substances or 2 hours thereafter.

15 The results obtained in these experiments showed how all the tested compounds, even if in different degrees, provide an effective protection both by oral and by parenteral administration.

From the evaluation of all the experimental results it is possible to conclude that the tested compounds are very effective in promoting the biosynthesis of intracellular GSH. In the test  
20 concerning the protection of the sound animal from the acute toxic effects of NAPA, this characteristic is particularly evident.

With respect to 2-methyl-thiazolidine-4-carboxylic acid used as such as reference compound, the compounds according to invention showed, in equimolecular amounts, a protective dose value, PD<sub>50</sub>,  
25 form 3 to 6 times lower.

The protection ensured by administering an extemporaneous association of 2-methyl-thiazolidine-4-carboxylic acid and the respective amino acid was also lower than that obtained by administering an equimolecular amount of the corresponding compound of formula i.

30 For example, the extemporaneous administration of 2-methyl-

- 7 -

thiazolidine-4-carboxylic acid and arginine is practically ineffective.

By the point of view of pharmacological activity the preferred  
5 compounds of formula I are those in which the amino acid is in esterified form (R=alkyl), and in particular the compounds in which 2-methyl-thiazolidine-4-carboxylic acid is bonded by peptidic bond to methionine, beta-alanine or proline.

The tested compounds have also a good general and local tolera-  
10 bility in the selected administration ways: oral and parenteral.

In both cases, no secondary effect was evidenced in the mouse also after 72 hours from administration and with doses as high as 2 g/kg.

Object of the present invention are also the pharmaceutical  
15 compositions containing as active ingredient a compound of formula I or an acceptable salt thereof.

Said compositions contain the active ingredient in association with an organic or inorganic, solid or liquid pharmaceutically acceptable carriers; according to the prescriptions, the composi-  
20 tions may be administered orally, parenterally, intramuscularly, intravenously or by inhalation.

The pharmaceutical preparations may be solid like tablets, pills, capsules, powders, granulates or liquid like solutions, suspensions, emulsions.

25 They may be prepared so as to ensure a time lasting release of the active ingredient after administration.

Beside the carriers, the compositions may also contain preservatives, stabilizers, wetting agents, emulsifiers, salts to regulate the osmotic pressure, buffers, dyes, flavorings, etcetera.

30 The compositions, which may also contain other active ingredients,

- 8 -

are prepared according to conventional procedures.

The therapeutical dose to be administered depends on different factors such as the seriousness of the pathologic state, the  
5 selected administration way, the specific characteristics of the selected compound of formula I, etcetera.

Daily dosages comprised between 2 and 20 mg/kg (body weight) may be considered; as antidote in the case of acute poisoning, said doses may be increased up to 4-6 g in total.

10 With the scope of better illustrating the invention, the following examples are given.

Example 1

Preparation of N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carboxylic acid.

15 To a suspension of 2-methyl-thiazolidine-4-carboxylic acid (10 g, 67.9 mmol) in dimethylformamide (37 ml) kept under stirring at room temperature, tetramethylguanidine (17 ml, 135.8 mmol) was added.

The solution was cooled at 10-15°C and t.butoxycarbonylazide (14.6  
20 g, 102 mmol) was slowly added.

After 48 hours at room temperature, the solution was evaporated to dryness under vacuum.

The solid residue was collected with ethyl acetate and the solution was washed with an aqueous solution of citric acid at 10%  
25 conc. and then with water.

The organic phase was dried on sodium sulphate then evaporated to dryness under vacuum.

The residue was collected with petroleum ether and the precipitate was filtered and dried.

30 N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carboxylic acid (11.9

- 9 -

g) was thus obtained.

$[\alpha]_D^{20} = -70^\circ$  (c=1, DMF)

m.p.=115-116°C

5  $R_f=0.78$  (AcOEt:Py:AcOH:H<sub>2</sub>O=120:10:3:5.5)

### Example 2

Preparation of (2-methyl-thiazolidin-4-carbonyl)-glycine methyl ester hydrochloride.

To a solution of glycine methyl ester hydrochloride (4.57 g, 36.4  
10 mmol) in dimethylformamide (100 ml) kept under stirring at -5°C, N-methyl-morpholine (4.01 ml, 36.4 mmol) and then a solution of N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carboxylic acid (9 g, 36.4 mmol) in dimethylformamide (20 ml) were added.

To the resulting solution kept under stirring at -5°C, dicyclo-  
15 hexylcarbodiimide (9 g, 43.68 mmol) and N-hydroxy-benzotriazole (5.89 g, 43.68 mmol) were added.

After 24 hours under stirring at +4°C, the precipitate (dicyclo-hexylurea) was filtered and the filtrate was evaporated to dryness.

20 An oil was obtained which was dissolved in ethyl acetate and the solution was washed with an aqueous solution of citric acid at 10%, with an aqueous sodium bicarbonate solution at 10% and with water.

The organic solution, dried on sodium sulphate was evaporated to  
25 dryness under vacuum at 40°C.

(N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carbonyl)-glycine methyl ester (9.48 g) was thus obtained as oil.

The obtained product (6.5 g) was treated at room temperature under nitrogen, with ethyl acetate (100 ml) containing 15% (w/v) of  
30 hydrogen chloride.

- 10 -

After 1 hour the solution was evaporated to dryness under vacuum at 35°C.

The residue, after crystallization from isopropyl alcohol, afforded (2-methyl-thiazolidine-4-carbonyl)-glycine methyl ester hydrochloride (4.7 g)

$$[\alpha]_D^{20} = -80^\circ \quad (c=1, \text{CH}_3\text{OH})$$

m.p.=75-76°C

$R_f=0.8$  (AcOEt:Py:AcOH:H<sub>2</sub>O=120:10:3:5.5)

### 10 Example 3

Preparation of (2-methyl-thiazolidine-4-carbonyl)-L-alanine methyl ester hydrochloride.

To a solution of L-alanine methyl ester hydrochloride (5.05 g, 36.4 mmol) in dimethylformamide (60 ml) kept under stirring at 15 -5°C, N-methyl-morpholine (4.01 ml, 36.4 mmol) and then a solution of N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carboxylic acid (10 g, 36.4 mmol) in dimethylformamide (20 ml) were added.

To the resulting solution kept under stirring at -5°C, dicyclohexylcarbodiimide (9 g, 43.68 mmol) and N-hydroxy-benzotriazole 20 (5.89 g, 43.68 mmol) were added.

After 24 hours under stirring at +4°C, the precipitate (dicyclohexylurea) was filtered and the filtrate was evaporated to dryness.

An oil was obtained which was dissolved in ethyl acetate and the 25 solution was washed with an aqueous solution of citric acid at 10%, with an aqueous sodium bicarbonate solution at 10% and with water.

The organic solution, dried on sodium sulphate was evaporated to dryness under vacuum at 40°C.

30 (N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carbonyl)-L-alanine

- 11 -

methyl ester (10.1 g) was thus obtained as oil.

The obtained product (8.2 g) was treated at room temperature under nitrogen, with ethyl acetate (100 ml) containing 13% (w/v) of  
5 hydrogen chloride.

After 1 hour the solution was evaporated to dryness under vacuum at 35°C.

The residue, after crystallization from isopropyl alcohol diethyl ether, afforded (2-methyl-thiazolidine-4-carbonyl)-L-alanine  
10 methyl ester hydrochloride (5.1 g) as raw product.

The product was purified by chromatography on a silica gel column (eluent ethyl acetate, pyridine, acetic acid, water in the ratio 120:10:3:5.5) and crystallized from ethyl acetate/petroleum ether.

$[\alpha]_D^{20} = -107^\circ$  (c=1, CH<sub>3</sub>OH)

15 m.p.=80-81°C

R<sub>f</sub>=0.8 (AcOEt:Py:AcOH:H<sub>2</sub>O=120:10:3:5.5)

#### Example 4

Preparation of (2-methyl-thiazolidin-4-carbonyl)-beta-alanine methyl ester.

20 To a solution of beta-alanine methyl ester hydrochloride (5.08 g, 36.4 mmol) in dimethylformamide (35 ml) kept under stirring at -5°C, N-methyl-morpholine (4.01 ml, 36.4 mmol) and then a solution of N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carboxylic acid (9 g, 36.4 mmol) in dimethylformamide (15 ml) were added.

25 To the resulting solution kept under stirring at -5°C, dicyclohexylcarbodiimide (9 g, 43.68 mmol) and N-hydroxy-benzotriazole (5.89 g, 43.68 mmol) were added.

After 24 hours under stirring at +4°C, the precipitate (dicyclohexylurea) was filtered and the filtrate was evaporated to dry-  
30 ness.

- 12 -

An oil was obtained which was dissolved in ethyl acetate and the solution was washed with an aqueous solution of citric acid at 10%, with an aqueous sodium bicarbonate solution at 10% and with  
5 water.

The organic solution, dried on sodium sulphate was evaporated to dryness under vacuum at 40°C.

(N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carbonyl)-beta-alanine methyl ester (10.7 g) was thus obtained as oil.

- 10 The obtained product (7.9 g) was treated at room temperature under nitrogen, with ethyl acetate (90 ml) containing 13% (w/v) of hydrogen chloride.

After 1 hour the solution was evaporated to dryness under vacuum at 35°C.

- 15 The residue, after crystallization from isopropyl alcohol diethyl ether, afforded (2-methyl-thiazolidine-4-carbonyl)-beta-alanine methyl ester hydrochloride (5.4 g).

$$[\alpha]_D^{20} = -85^\circ \quad (c=1, \text{CH}_3\text{OH})$$

m.p.=124-125°C

- 20  $R_f = 0.74$  (AcOEt:Py:AcOH:H<sub>2</sub>O=120:10:3:5.5)

#### Example 5

Preparation of (2-methyl-thiazolidine-4-carbonyl)-beta-alanine hydrochloride.

- To a solution of (N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carbonyl)-beta-alanine methyl ester (4.2 g, 12.6 mmol) in methanol  
25 (25 ml), 1N sodium hydroxide (25.2 ml, 25.2 mmol) was added at room temperature.

After 1.5 hours the solution was concentrated under vacuum at 40°C and, after cooling at 0°C, it was acidified by citric acid up to  
30 pH 3.



- 13 -

(N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carbonyl)-beta-alanine (2.93 g) precipitated, it was separated by filtration, washed with water and dried (m.p.=117-118°C).

5 The obtained product (1.55 g, 4.87 mmol) was dissolved, at room temperature and under nitrogen, in ethyl acetate (45 ml) containing 13% (w/v) of hydrogen chloride.

After 15 minutes diethyl ether was added and (2-methyl-thiazolidine-4-carbonyl)-beta-alanine (1.1 g) precipitated, it was collected by filtration, washed and dried.

$[\alpha]_D^{20} = -94^\circ$  (c=1, CH<sub>3</sub>OH)

$R_f = 0.38$  (AcOEt:Py:AcOH:H<sub>2</sub>O=120:10:3:5.5)

#### Example 6

Preparation of (2-methyl-thiazolidin-4-carbonyl)-L-methionine methyl ester hydrochloride.

To a solution of L-methionine methyl ester hydrochloride (9.75 g, 48.8 mmol) in dimethylformamide (50 ml) kept under stirring at -5°C, N-methyl-morpholine (5.35 ml, 48.8 mmol) and then a solution of N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carboxylic acid (11 g, 44.4 mmol) in dimethylformamide (20 ml) were added.

To the resulting solution kept under stirring at -5°C, dicyclohexylcarbodiimide (11 g, 53.4 mmol) and N-hydroxy-benzotriazole (7.2 g, 53.4 mmol) were added.

After 24 hours under stirring at +4°C, the precipitate (dicyclohexylurea) was filtered and the filtrate was evaporated to dryness.

An oil was obtained which was dissolved in ethyl acetate and the solution was washed with an aqueous solution of citric acid at 10%, with an aqueous sodium bicarbonate solution at 10% and with water.

- 14 -

The organic solution, dried on sodium sulphate was evaporated to dryness under vacuum at 40°C.

(N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carbonyl)-L-methionine  
5 methyl ester (13.5 g) was thus obtained as oil.

The obtained product was treated at room temperature under nitrogen, with ethyl acetate (45 ml) containing 13% (w/v) of hydrogen chloride.

After 1 hour the solution was evaporated to dryness under vacuum  
10 at 35°C.

The residue, after crystallization from isopropyl alcohol diethyl ether, afforded (2-methyl-thiazolidine-4-carbonyl)-L-methionine methyl ester hydrochloride (3.9 g).

$[\alpha]_D^{20} = -94^\circ$  (c=1. CH<sub>3</sub>OH)

15 m.p.=115-116°C

R<sub>f</sub>=0.8 (AcOEt:Py:AcOH:H<sub>2</sub>O=120:10:3:5.5)

#### Example 7

Preparation of (2-methyl-thiazolidin-4-carbonyl)-L-proline methyl ester hydrochloride.

20 To a solution of L-proline methyl ester hydrochloride (3.68 g, 22.2 mmol) in dimethylformamide (25 ml) kept under stirring at -5°C, N-methyl-morpholine (2.45 ml, 22.2 mmol) and then a solution of N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carboxylic acid (5 g, 20.2 mmol) in dimethylformamide (10 ml) were added.

25 To the resulting solution kept under stirring at -5°C. dicyclohexylcarbodiimide (5.03 g, 24.4 mmol) and N-hydroxy-benzotriazole (3.29 g, 24.4 mmol) were added.

After 24 hours under stirring at +4°C, the precipitate (dicyclohexylurea) was filtered and the filtrate was evaporated to dryness.  
30

- 15 -

An oil was obtained which was dissolved in ethyl acetate and the solution was washed with an aqueous solution of citric acid at 10%, with an aqueous sodium bicarbonate solution at 10% and with  
5 water.

The organic solution, dried on sodium sulphate was evaporated to dryness under vacuum at 40°C.

(N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carbonyl)-L-proline methyl ester (5.47 g) was obtained by crystallization of the  
10 residue from ethanol at 10% (v/v).

$[\alpha]_D^{20} = -139^\circ$  (c=1, CH<sub>3</sub>OH)

m.p.=105-106°C

The obtained product (2.6 g, 7.25 mmol) was treated at room temperature under nitrogen, with ethyl acetate (50 ml) containing  
15 13% (w/v) of hydrogen chloride.

After 15 minute the solution was evaporated to dryness under vacuum at 35°C.

The residue, after crystallization from diethyl ether, afforded (2-methyl-thiazolidine-4-carbonyl)-L-proline methyl ester hydro-  
20 chloride (1.8 g).

$[\alpha]_D^{20} = -179^\circ$  (c=1, CH<sub>3</sub>OH)

R<sub>f</sub>=0.8 (AcOEt:Py:AcOH:H<sub>2</sub>O=120:10:3:5.5)

#### Example 8

Preparation of (2-methyl-thiazolidin-4-carbonyl)-beta-alanine  
25 methyl ester hydrochloride.

The preparation in example 4 was repeated by using 150 g (0.725 mol) of N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carboxylic acid.

The (2-methyl-thiazolidin-4-carbonyl)-beta-alanine methyl ester  
30 was crystallized from petroleum ether.

- 16 -

The obtained product  $\underline{220}$  g,  $[\alpha]_D^{20} = -74^\circ$  (c=1, MeOH), m.p. =  $62^\circ\text{C}$  was treated at room temperature under nitrogen with ethyl acetate (950 ml) containing 13% (v/v) of hydrogen chloride.

5 After 1 hour the solution was evaporated to dryness under vacuum at  $35^\circ\text{C}$ .

The residue, after crystallization from isopropyl alcohol, afforded (2-methyl-thiazolidine-4-carbonyl)-beta-alanine methyl ester hydrochloride (145 g)

10  $[\alpha]_D^{20} = -93^\circ$  (c=1, MeOH)  
m.p. =  $129-130^\circ\text{C}$

$R_f = 0.74$  (AcOEt:Py:AcOH:H<sub>2</sub>O = 120:10:3:5.5)

#### Example 9

Preparation of (2-methyl-thiazolidin-4-carbonyl)-L-methionine  
15 methyl ester hydrochloride.

The preparation in example 6 was repeated by using 175 g (0.705 mol) of N-t.butoxycarbonyl-2-methyl-thiazolidine-4-carboxylic acid.

The (2-methyl-thiazolidin-4-carbonyl)-L-methionine methyl ester  
20 was crystallized from petroleum ether.

The obtained product  $\underline{163}$  g,  $[\alpha]_D^{20} = -76^\circ$  (c=1, MeOH), m.p. =  $65^\circ\text{C}$  was treated at room temperature under nitrogen with ethyl acetate (730 ml) containing 13% (v/v) of hydrogen chloride.

After 1 hour the solution was evaporated to dryness under vacuum  
25 at  $35^\circ\text{C}$ .

The residue, after crystallization from isopropyl alcohol/diethyl ether, afforded (2-methyl-thiazolidine-4-carbonyl)-L-methionine methyl ester hydrochloride (104 g).

30  $[\alpha]_D^{20} = -100^\circ$  (c=1, MeOH)  
m.p. =  $119-120^\circ\text{C}$

- 17 -

$R_f = 0.8$  (AcOEt:Py:AcOH:H<sub>2</sub>O=120:10:3:5.5)

5

10

15

20


25

30

- 18 -

C l a i m s

1) A compound of formula

wherein the group  $\text{-N}-(\text{Y})-\text{COOR}$ 

represents the residue of a natural amino acid selected from the group consisting of glycine, alanine, beta-alanine, phenylalanine, isoleucine, methionine, proline, aspartic acid and arginine;


R represents a hydrogen atom or a  $\text{C}_1-\text{C}_4$  alkyl;

and their acid-addition salts with pharmaceutically acceptable organic or inorganic acids.

2) A compound according to claim 1 in which R represents a  $\text{C}_1-\text{C}_4$  alkyl.

3) A pharmaceutically acceptable acid-addition salt of a compound according to claim 1 in which R represents a  $\text{C}_1-\text{C}_4$  alkyl.

4) A compound according to claim 1 in which the group



represents the residue of an amino acid selected from methionine, beta-alanine and proline.

5) A method for the preventive and curative treatment of pathologic syndromes due to the depletion of the glutathione (GSH) content in the parenchymal organs and in the mesenchymal cellular population, said method consisting in administering a therapeutically effective amount of a compound of claim 1.

6) A method for the preventive or curative treatment of toxic or toxoinfective hepatopathy, of respiratory affections having infec-

- 19 -

tive origin or originated by inhalation of extraneous substances, of arthritis, of degenerative cardiopathy during chemotherapy or of central or peripheral neuropathy due to depletion of glutathione (GSH) levels, said method consisting in administering a therapeutically effective amount of a compound according to claim 1.

7) A pharmaceutical composition containing as active ingredient a compound according to claim 1 beside pharmaceutically acceptable carriers.

8) A pharmaceutical composition for the preventive and curative treatment of pathologic syndromes due to the depletion of the glutathione (GSH) content in the parenchymal organs and in the mesenchymal cellular population.

9) A pharmaceutical composition for the preventive or curative treatment of toxic or toxoinfective hepatopathy, of respiratory affections having infective origin or originated by inhalation of extraneous substances, of arthritis, of degenerative cardiopathy during chemotherapy or of central or peripheral neuropathy due to depletion of glutathione (GSH) levels.

20

25

30

# INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 85/00543

## I. CLASSIFICATION & SUBJECT MATTER (If several classification symbols apply, indicate all)

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC<sup>4</sup>: C 07 K 5/06; A 61 K 37/02; // C 07 K 5/02

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>1</sup>

Classification System |

Classification Symbols

IPC<sup>4</sup>                      C 07 K 5/00  
                                 A 61 K 37/00

Documentation Searched other than Minimum Documentation  
to the extent that such documents are included in the Fields Searched<sup>1</sup>

## III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>2</sup>

Category <sup>3</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	EP, A, 0048159 (UNIVERSITY OF MIAMI) 4 March 1982, see title page; pages 1-53, 99-120; claims; pages 1-9	1-3, 7
Y	EP, A, 0012401 (MERCK) 25 June 1980, see title page; pages 1-7, 84-98	1-3, 7
Y	EP, A, 0050800 (SCHERING) 5 May 1982, see title page; pages 1-29, 77-97	1-3, 7
A	Chemical Abstracts, volume 88, 1978, Columbus, Ohio, (US) J. Savrda: "Cis-trans isomerism of N-acyl derivatives of proline and its analogs. Linear peptides with cis peptide bonds", see page 502, abstract no. 74527r & Pept. Proc. Eur. Pept. Symp., 14th 1976, 653-6 (Eng)	1, 7
P, A	DE, A, 3332633 (LUITPOLD) 4 April 1985, see title page; pages 77-81	1, 7.
A	Chemical Abstracts, volume 95, 1981, Columbus, Ohio, (US)	./.

\* Special categories of cited documents: 10

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Δ" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

26th January 1986.

Date of Mailing of this International Search Report

19 FEB. 1986

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

*[Signature]*

M. VAN NIEU



III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
----------	------------------------------------------------------------------------------------	----------------------

	see pag 732, abstract no. 204439w DE 3024256 (RICHTER GEDEON) 8 January 1981	1,7
	-----	

# ANNEX TO THE INTERNATIONAL SEARCH REPORT ON

INTERNATIONAL APPLICATION NO. PCT/EP 85/00543 (SA 11098)

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 12/02/86

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0048159	24/03/82	JP-A- 57126468	06/08/82
		AU-A- 7529581	25/03/82
		JP-A- 58035114	01/03/83
EP-A- 0012401	25/06/80	AU-A- 5346179	19/06/80
		JP-A- 55081845	20/06/80
		US-A- 4374829	22/02/83
		AU-B- 530380	14/07/83
		AT-B- E6503	15/03/84
EP-A- 0050800	05/05/82	JP-A- 57112359	13/07/82
		AU-A- 7661481	29/04/82
		OA-A- 6929	31/05/83
		US-A- 4470972	11/09/84
DE-A- 3332633	04/04/85	None	

For more details about this annex :  
see Official Journal of the European Patent Office, No. 12/82